Peringkat dalam Saham
#23616
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on... MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
Harga Saham
$3.78
Terakhir disinkronkan: 2026-08-21
Kapitalisasi Pasar
$71.20M
Perubahan (1 tahun)
-43.37%
Perdagangan MaaT Pharma S.A. (MAAT)
Harga MAAT dengan kapitalisasi pasar B
Kapitalisasi pasar dari MaaT Pharma S.A.(MAAT)
Kapitalisasi Pasar: $71.20M
Per August 2026, MaaT Pharma S.A. memiliki kapitalisasi pasar sebesar $71.20M. Ini menjadikan MaaT Pharma S.A. sebagai perusahaan 23616th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar MaaT Pharma S.A. dari 2021 hingga 2026
MAAT dibandingkan dengan 5 teratas stocks paling populer
| Harga MAAT |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.211T
|
+7,318,865.32%
|
|
|
|
|
$4.547T
|
+6,385,453.75%
|
|
|
|
|
$4.162T
|
+5,845,776.17%
|
|
|
|
|
$3.593T
|
+5,045,697.23%
|
|
|
|
|
$2.793T
|
+3,922,248.30%
|
